Profile data is unavailable for this security.
About the company
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
- Revenue in USD (TTM)33.25m
- Net income in USD-23.09m
- Incorporated2015
- Employees85.00
- LocationBiofrontera Inc120 Presidential Way,, Suite 330WOBURN 01801United StatesUSA
- Phone+1 (781) 245-1325
- Fax+1 (302) 655-5049
- Websitehttps://www.biofrontera-us.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemtech Corp | 4.64m | -4.08m | 5.41m | 45.00 | -- | -- | -- | 1.17 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 5.49m | 8.00 | -- | 0.276 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.51m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Biofrontera Inc | 33.25m | -23.09m | 5.52m | 85.00 | -- | -- | -- | 0.1661 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Ainos Inc | 93.68k | -14.56m | 5.53m | 46.00 | -- | 0.2384 | -- | 59.03 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -11.24m | 5.55m | 4.00 | -- | 0.8677 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.56m | 4.00 | -- | 0.5595 | -- | 0.6939 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| Clever Leaves Holdings Inc | 17.42m | -19.80m | 5.56m | 296.00 | -- | 0.2262 | -- | 0.3194 | -12.57 | -11.38 | 11.11 | 14.02 | 0.418 | 1.69 | 11.03 | 58,841.21 | -47.51 | -23.20 | -58.14 | -26.55 | 37.64 | -- | -113.66 | -207.52 | 1.63 | -3.70 | 0.0479 | -- | 6.14 | -- | 47.63 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.61m | 4.00 | -- | 0.6106 | -- | 623.13 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.34m | 5.65m | 2.00 | -- | -- | -- | -- | -0.0102 | -0.0102 | 0.00 | -0.0002 | 0.00 | -- | -- | -- | -62,992.45 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -12.23m | 5.69m | 5.00 | -- | 0.2269 | -- | -- | -37.38 | -37.38 | 0.00 | 21.08 | 0.00 | -- | -- | 0.00 | -13.75 | -40.33 | -15.54 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 5.69m | 15.00 | -- | 0.259 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 5.71m | 389.00 | 0.001 | 0.0001 | 0.6189 | 0.1003 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 5.72m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 5.74m | 7.00 | -- | 0.8327 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Biofrontera Inc's reporting currency: US Dollar USD
22.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 13 May 2024 | 504.26k | 9.91% |
| AIGH Capital Management LLCas of 15 Apr 2024 | 501.43k | 9.85% |
| Matejka & Partner Asset Management GmbHas of 29 Feb 2024 | 63.80k | 1.25% |
| Scotia Capital, Inc. (Broker)as of 31 Mar 2024 | 40.00k | 0.79% |
| XTX Markets LLCas of 31 Mar 2024 | 12.19k | 0.24% |
| HRT Financial LLCas of 31 Mar 2024 | 10.64k | 0.21% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 10.22k | 0.20% |
| amandea Verm�gensverwaltung AGas of 31 Dec 2022 | 10.00k | 0.20% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.62k | 0.09% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.91k | 0.04% |
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
